The subject was founded Nov 2007 as a joint venture between BIDIPHAR I PHARMACEUTICAL JOINT STOCK COMPANY, Vietnamese individuals and FRESENIUS KABI AG – a giant in infusion therapy and clinical nutrition in Europe. After the withdrawal of BIDIPHAR, the subject has changed name to FRESENIUS KABI VIETNAM JOINT STOCK COMPANY since 2018. The subject focuses on manufacturing and trading in pharmaceutical products, materials and machines, equipment related to medical. Its main supplier is Fresenius Kabi Asia Pacific Ltd – a member of Fresenius Kabi Group. Besides the local market, its products are also provided for Asian countries. Under the rise of materials price in general, its profitability reduced remarkably since 2021 but generally, its business performance was still good. It remained a strong financial structure.
Headquarters
Area 8, Nhon Phu Ward
Binh Dinh; South Central Coastal Vietnam;
Postal Code: 55000
Contact Details: Purchase the Fresenius Kabi Vietnam Joint Stock Company report to view the information.
Website: https://www.fresenius-kabi.com/vn/company/fresenius-kabi-viet-nam
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service
